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Frequent loss of heterozygosity of microsatellites markers on speciﬁc chromosomal region have been reported in various
types of primary human cancer. The same loss of heterozygosity has also been identiﬁed in the matched plasma/serum DNA.
Using 109 microsatellite markers representing 24 chromosomal arms, we have examined the loss of heterozygosity in 21 cases
of hepatocellular carcinoma, six of cholangiocarcinoma, and 27 cases of chronic hepatitis or cirrhosis. All cases of the
hepatocellular carcinoma showed deletion from two to 10 chromosomal arms, while deletion of chromosomes from two to
eight regions was detected in ﬁve of six cholangiocarcinoma patients. One or more loss of heterozygosity in the paired serum
DNA could be detected in 16 of 25 (76.2%) hepatocellular carcinoma patients. In contrast, no alterations in serum DNA test
could be found in cholangiocarcinoma patients. Five of seven (71.4%) hepatocellular carcinoma patients with alpha-fetoprotein
levels less than 20 ng ml
71 produced positive serum DNA test. The proﬁles of 19 microsatellite markers gave a 100%
positive predictive value and an 80.8% negative predictive value for hepatocellular carcinoma. In conclusion, we have
determined a proﬁle of microsatellite markers appropriate for differential diagnosis of primary liver cancer. The discovery may
permit a high-throughput screening of hepatocellular carcinoma at an early stage of disease.
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Primary liver cancer ranks ﬁfth in frequency among all malignan-
cies in the world with an estimated number of 437 000 new cases
in 1990. The vast majority of primary liver cancer is hepatocellular
carcinoma (HCC), a malignant tumour derived from hepatocytes.
HCC is increasing in many countries, particularly in areas where
hepatitis C virus infection is more common than hepatitis B virus
infection (El-Serag and Mason, 1999). The cholangiocarcinoma
(CC), an intrahepatic malignant tumour which arises in the epithe-
lium of the bile ducts, is the second common hepatic tumour. Its
occurrence is largely high in areas where liver ﬂuke infestation or
intrahepatic stones is endemic, such as Hong Kong, Thailand
and Taiwan (Okuda et al, 1977).
The prognosis of HCC or CC is usually poor, with 3-year survi-
val rates estimated at 44.9% and 34% after hepatic resection,
respectively (Okuda et al, 1977). In patients with symptomatic
HCC, the tumours are usually either too large and/or with local
invasion or distant metastasis. Therefore, only 10–20% of patients
could be treated with potentially curative therapy, while the
remaining patients can only receive non-surgical therapy, such as
a transcatheter arterial embolisation or other local ablation treat-
ments with a less satisfactory outcome. The patients with CC
often present with obstructive jaundice at the stage of advanced
stage. Currently, resection offers the only chance of cure and the
best chance of long-term survival.
In order to improve the chances of successful treatment and
patient survival, great effort has been devoted to detect HCC in
the early stage when it is ‘small’, for example smaller than 3 cm,
and where liver function reserve is good enough for curative ther-
apy. Measurement of serum a-fetoprotein (AFP) and hepatic
ultrasonography are widely used as surveillance modalities for
high-risk patients. Elevated levels of AFP, with normal range set
at 20 ng ml
71, are detected in up to 75% of HCC patients, and
values above 400 ng ml
71 are considered diagnostic for HCC
(Ebara et al, 1986). However, 35% of HCC smaller than 3 cm
may secrete little or no AFP into the circulation and thus will
not be identiﬁed by this test (Ebara et al, 1986). As a result,
measurement of AFP alone is not an ideal test for early diagnosis
of HCC.
Recent advances in tumour genetics reveal that the genesis and
progression of tumours follow an accumulation of multiple genet-
ic alterations, including inactivation of tumour suppressor genes
and/or activation of proto-oncogenes. Frequent loss of heterozyg-
osity (LOH) of microsatellites markers on speciﬁc chromosomal
region have been reported in various types of human cancer. In
addition, nucleic acid-based molecular techniques have success-
fully identiﬁed the same LOH in the paired plasma/serum DNA
from patients with diverse types of epithelial cancer, such as lung
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www.bjcancer.com(Chen et al, 1996; Sozzi et al, 1999, 2001), head and neck (Coulet
et al, 2000; Nunes et al, 2001), colon (Hibi et al, 1998), breast
(Chen et al, 1999; Silva et al, 1999), kidney (Goessl et al, 1998;
Eisenberger et al, 1999). The results indicate that microsatellite
DNA analysis may have potential as a non-invasive test for cancer
diagnosis. In this pilot study, we have searched for the genetic
alterations, using a total of 109 microsatellite markers representing
24 chromosomal regions, in the serum DNA of patients with
primary liver cancer, i.e. HCC (n=21) and CC (n=6). The results
suggest that microsatellite serum DNA analysis may be a valuable,
non-invasive method for the early detection of primary liver
cancer.
MATERIALS AND METHODS
Sample collection and DNA preparation
Primary tumour from 21 cases of HCC and six cases of CC
were collected from the Department of Surgery, National Cheng
Kung University Hospital, Tainan, Taiwan between September
1998 and March 2000 (Tables 1 and 2). The tumour tissue
was obtained immediately after surgical resection and stored
at 7808C, and then microdissected as described in detail
previously (Eisenberger et al, 1999). We also enrolled 27
patients (age- and sex-matched) with a biopsy diagnosis of
chronic hepatitis (n=20) or cirrhosis (n=7) as controls. Both
peripheral blood lymphocytes and serum samples were obtained
with written informed consent. Brieﬂy, DNA was extracted from
peripheral blood lymphocytes, tumour and matched serum
samples by digestion with 1% SDS/proteinase K (BD Biosciences
Clontech, CA, USA) overnight followed by phenol-chloroform
extraction and ethanol precipitation. Each tumour was reviewed
for histologic grading according to the Edmondson classiﬁcation
(1958). Clinical staging was determined according to the
tumour-node-metastasis staging protocol of the American Joint
Committee on Cancer (1997) with surveys of the clinical details,
image studies, and pathologic data. The clinical characteristics,
including AFP, hepatitis B surface antigen (HBsAg) and hepati-
tis C virus antibody (anti-HCV), were obtained from medical
records.
Analysis for allelic loss
Microsatellite markers from selected chromosomal arms for PCR
analysis were obtained from Research Genetics (Huntsville, AL,
USA). The marker pairs selected for HCC (74 markers from 17
chromosomal arms) included 1p (D1S160, D1S163, D1S170,
D1S186, MYCL), 3p (D3S1317), 4p (D4S394), 4q (D4S398,
D4S395, D4S392, D4S422, FGA, FABP2, D4S427, D4S415,
D4S1615, D4S1554, D4S1426, D4S1598, D4S620, D4S1566,
D4S1545, D4S2920, D4S2943, D4S2954), 5q (D5S409), 6q
(D6S264), 8p (D8S261, D8S277), 8q (D8S85, D8S200, D8S555,
D8S283), 9p (D9S169, D9S1747, D9S104), 10q (D10S109), 11p
(D11S554, D11S436, D11S1344, D11S932, D11S1324), 11q
(D11S938, D11S29), 12p (D12S93), 13q (D13S171, D13S153,
Rb1, D13S133, D13S227, D13S159, D13S166, D13S168), 14q
(D14S72, D14S51), 16p (D16S419, D16S409, D16S3106,
D16S498), 16q (D16S415, D16S408, D16S512, D16S289,
D16S402, D16S516, D16S422, D16S413), and 17p (D17S520,
D17S1176, TP53, D17S513, D17S578, D17S796, D17S849) based
on previous reports (Yeh et al, 1996; Nagai et al, 1997; Piao et
al, 1998; Fujii et al, 2000; Okabe et al, 2000; Yeh et al, 2001).
The marker pairs selected for CC (35 markers from 16 chromoso-
mal arms) included 2p (BAT-26), 3p (D3S3667, D3S1578,
D3S3582, D3S3560, D3S1581, D3S3729, D3S1588, D3S3648), 4
(D4S415, D4S413), 5q (D5S323, D5S417), 6p (D6S263), 6q
(D6S292), 7q (D7S495, D7S486), 9p (D9S747, D9S171), 11p
(D11S907, D11S569), 14q (D14S1436), 16q (D16S3094, D16S511,
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Table 1 Clinical characteristics of patients with hepatocellular carcinoma
Size Stage HBsAg/ AFP Positive markers
No. Age/Sex (cm) Grade (AJCC) anti-HCV Deleted chromosomes (ng ml
71) in serum DNA
1 40/M 3.6 II III +/7 3p, 4q, 8p, 16p, 16q, 17p, 18 3200 None detected
2 55/F 2.5 I II +/7 1p, 3p, 9p, 13q, 17p 18
a D1S170
3 62/F 4.2 II II +/7 1p, 3p, 8q, 9p, 14q, 16p, 16q, 17p 15.7
a D1S160, D14S51, D16S402, D16S422
4 47/M 1.5 II I +/ND
b 3p, 4q, 8q, 9p, 13q, 14q, 16q, 17p 230 D9S171, D16S289
5 45/M 13.5 II IV +/7 1p, 4q, 5q, 8p, 8q, 9p, 13q, 14q, 16q, 17p 4450 D1S163, D5S409
6 31/F 10.0 I III +/7 1p, 4q, 8p, 9p, 13q, 14q, 16p, 16q, 17p 44180 D9S747
7 44/M 4.0 II II +/7 9p, 14q, 16q, 17190 D16S498
8 48/M 14.0 IV IV 7/7 1p, 8q, 13q, 14q, 16q 165000 D1S163, D8S555
9 51/M 4.0 III II +/7 1p, 10q, 14q, 16q, 17p 6.9
a D1S163
10 40/M 4.5 II II 7/+ 1p, 4q 10q, 13q, 14q 1.4
a D1S170
11 64/M 3.5 III II 7/+ 1p, 4q, 8p, 13q, 16p, 16q, 17p 2560 D13S227
12 66/M 5.0 II II 7/+ 1p, 3p, 4q, 5q, 8p, 8q, 11p 998.2 D1S170, D11S1344
13 71/M 10.0 III IV +/7 1p, 4q, 5q, 8p, 9p, 13q, 14q, 16q, 17p 642.3 D9S171
14 65/F 2.2 II II 7/+ 4q, 16q 127 D4S1545
15 41/M 1.8 II II +/ND
b 4q, 8p, 11p, 16q 435 None detected
16 50/M 20.0 I II ND
b 5q, 7q, 8q, 16p, 16q, 17p 3452 D5S409, D7S495, D8S200
17 61/M 4.0 I II +/+ 3p, 10q 5.8
a None detected
18 44/M 14.0 II II +/ND
b 1p, 8p, 16p 15.2
a None detected
19 56/M 2.2 IV III 7/+ 4q, 8p, 9p, 13q, 17p 215.8 D4S1545
20 60/M 2.5 I II ND
b 1p, 4q, 5q, 8p, 13q 232 None detected
21 65/F 1.3 I I 7/+ 9p, 16p, 16q, 17p 13
a D16S402, D16S516, D16S419
aAFP lower than 20 ng ml
71.
bND=None detected.
Table 2 Clinical characteristics of patients with cholangiocarcinoma
Size Stage Deleted
No. Age/Sex (cm) Grade (AJCC) chromosomes
22 62/F 1.2 III III 4q, 14q
23 75/M 5.0 I III 3p, 4q, 8p, 9p, 13q, 14q, 16q, 17p
24 60/M 3.5 I III No deletions
25 46/M 3.3 II III 3p, 4q, 9p, 16p, 17p
26 53/M 3.0 III III 8p, 9p, 16q, 17p
27 71/F 2.0 II II 11p, 17p
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D18S535), 20 (D20S85), 21q (D21S1245, D21S1436, D21S1270),
and Xp (DXS538) (Ding et al, 1993; Fujii et al, 2000). All of the
tumours, irrespective of histopathology, were analysed for a total
of 109 microsatellite markers (74 markers for HCC and 35 markers
for CC) to conﬁrm the speciﬁcity of chromosomal alterations as
well as their presence in the serum as tumour markers.
Prior to ampliﬁcation, one primer from each pair was end-
labelled with [g-
32P]ATP (20 mCi; Amersham Pharmacia Biotech
Inc., NJ, USA) and T4 kinase (New England Biolabs Inc., MA,
USA) (Eisenberger et al, 1999). The ampliﬁcation conditions for
polymerase chain reaction (PCR) were 16 buffer (GibcoBRL,
NY, USA), 1.5 mM MgCl2, 0.6 mM dNTP, 5 pmol of each primer,
1.0 ml g-
32P-labelled primer, 4 ml DNA, and 0.1 ml of Taq DNA
polymerase (GibcoBRL, NY, USA) in a total of 10 ml. PCR for each
primer set was performed for 35 cycles consisting of denaturation
at 958C for 30 s, annealing at 50–608C for 1 min, and extension at
708C for 1 min (Perkin-Elmer Gene Amp PCR System 9600,
Perkin-Elmer Corporation, MA, USA). The reaction products were
separated on 7% urea- formamide-polyacrylamide gels (GibcoBRL,
NY, USA) and exposed for 12–24 h. For informative tumours,
LOH was scored if the tumour allele demonstrated a greater than
30% reduction in intensity compared to the corresponding normal
control visually as previously described (Figure 1) (Eisenberger et
al, 1999). Each LOH was conﬁrmed by two independent experi-
ments. Allelic loss was determined by observation of LOH at any
informative marker mapped to the same chromosomal region.
Then, LOH analysis was performed on matched serum samples.
Statistical analysis
Allelic status was correlated with clinical and pathologic factors of
HCC, such as histological grading, disease stage, tumour size,
serum AFP levels, portal vein thrombosis and satellite nodule
formation by Fisher’s exact test. To evaluate the diagnostic accu-
racy in the microsatellite analysis, we considered four events: (A)
positive test: presence of LOH in the primary tumour and in the
matched serum DNA (true positive); (B) positive test: absence of
LOH in tumour but presence of LOH in patient serum (false posi-
tive); (C) negative test: presence of LOH in tumour but absence in
paired serum samples (false negative); and (D) negative test:
absence of LOH either in tumour or in paired serum samples (true
negative). Decision diagnostic criteria were obtained from the
results A, B, C, and D. Test sensitivity is equal to A/A+C. Test
speciﬁcity is equal to D/D+B. Test accuracy is equal to: A+D/
A+B+C+D. Predictive positive result or positivity prediction is
equal to A/A+B. Predictive negative result or negativity prediction
is equal to D/D+C.
RESULTS
All of the HCC cases showed deletion from two to 10 chromoso-
mal arms (Table 1). The highest incidence was 16q (66.7%),
followed by 1p (57.1%), 4q (57.1%), 8p (52.4%), 17p (52.4%),
13q (47.6%), 14q (42.9%), 9p (33.3%), 16p (33.3%), 3p (28.6%),
8q (28.6%), 5q (23.8%), 10q (14.3), 11p (9.5%), 18 (4.8%), and
7q (4.8%), respectively. The allelic losses were compared with
biologic indicators of HCC, such as histological grading, tumour
stage, size, and AFP serum levels (Table 1). A positive correlation
was observed for 4q with AFP greater than 20 ng ml
71 (P=0.02),
and 13q with satellite lesion (P=0.04) (data not shown). There
was a trend toward positive association of 8p or 13q loss with
advanced tumour staging (P=0.06), and 8p loss with AFP greater
than 20 ng ml
71 (P=0.06). LOH on 14q and 16q occurred more
frequently in hepatitis C virus-negative patients (P50.05, respec-
tively). Otherwise, patterns of allelic loss did not relate to
histological grading or tumour size (P40.1, respectively). In addi-
tion, novel alleles indicative of microsatellite instability were found
in three patients (cases 2, 3 and 7, respectively) at chromosome 2,
13 and 16, respectively (data not shown).
As for tumour diagnosis, a total of 16 of 21 (76.2%) HCC
patients were found to have LOH in serum DNA from one to four
microsatellite markers (Table 1). The presence of LOH in the
serum DNA did not relate to histological grading, staging or
tumour size (P40.1, respectively). If the cut-off values were set
at AFP 400 ng ml
71, negative serum LOH test was observed in
two of 10 (20%) patients with abnormal AFP level (cases 1 and
15), and in three of 11 (27.3%) patients having AFP level within
normal limits (case 17, 18 and 20). In contrast, ﬁve of seven
(71.4%) patients (cases 2, 3, 9, 10 and 21) having AFP less than
20 ng ml
71 had positive LOH test. The results imply that microsa-
tellite DNA analysis may have potential as a non-invasive
diagnostic test for the early detection of HCC, especially for those
who having AFP below reference range. However, none of three
cases showing microsatellite instability in primary tumours had
the same alterations detected in the serum DNA (data not shown).
With regard to cholangiocarcinoma, ﬁve of six patients belong
to advanced stage of tumour (Table 2). Deletion of chromosome
was detected from two to eight regions in ﬁve of six patients.
But, no any alterations in serum DNA test could be found, despite
of the fact that some common allelic losses were observed between
HCC and CC. The results seem to imply a limited potential of the
microsatellite analysis in diagnosing of CC.
Altogether, the data of this pilot study indicate that microsatel-
lite analysis of serum DNA could successfully detect around three-
quarters (76.2%) of HCC by screening the following proﬁle of
microsatellite markers, i.e. D1S160, D1S163, D1S170, D4S1545,
D5S409, D7S495, D8S200, D8S555, D9S171, D9S747, D11S1344,
D13S227, D14S51, D16S289, D16S402, D16S419, D16S422,
D16S498, D16S516. The positive predictive value was 100%, and
negative predictive value was 80.8%.
DISCUSSION
Currently, only ultrasound-guided needle biopsy yields diagnostic
material and allows a deﬁnitive differential diagnosis between
HCC and CC (Tsuji et al, 1999). Measurement of serum AFP
and hepatic ultrasonography are widely used as surveillance modal-
ities for patients with high-risk of liver cancer. In patients with
HCC, however, around one-third of small tumour (53 cm) was
shown to secrete little or no AFP into the circulatory system (Ebara
et al, 1986). As a result, it is mandatory to explore supplementary
tumour marker for early detection of HCC.
In this study, we detected one or more LOH in the serum DNA
in three-quarters of HCC patients. The results are comparable to
some prior reports showing microsatellite alterations in the plas-
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Figure 1 LOH was scored for if the tumour allele (T) had a greater than
30% reduction in intensity compared to the corresponding allele in the nor-
mal control (N). Identical loss, highlighted by arrowhead, was also demon-
strated in the matched serum (S).
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al, 1998; Hibi et al, 1998; Eisenberger et al, 1999; Silva et al,
1999; Sozzi et al, 1999, 2001; Coulet et al, 2000; Nunes et al,
2001). However, the sensitivity of microsatellite DNA test greatly
depends on the kind of cancer studied. For example, the detection
rate was 71% for small cell carcinoma of the lung (Chen et al,
1996), from 60 to 63% for renal cell carcinoma (Goessl et al,
1998; Eisenberger et al, 1999), between 48 and 66% for breast
cancer (Chen et al, 1999; Silva et al, 1999), from 40 to 45% for
non-small cell lung cancer (Sozzi et al, 1999, 2001), between less
than 2 and 18.7% for head and neck cancer (Coulet et al, 2000;
Nunes et al, 2001) using a set of primer pairs.
In contrast, the lack of tumour-speciﬁc LOH in the serum of CC
patients appears to correspond to the observation reported for
colon cancer (0%) (Hibi et al, 1998), though these patients may
still have very low levels of tumour-derived DNA. Nonetheless,
the difference appears to support the propensity of HCC to spread
to vascular system (portal vein and hepatic vein), whereas peri-
neural invasion and lymphatic involvement are frequently present
in CC at an early stage (Sasaki et al, 2001). Taken together, the
data support the detection of circulating tumour-derived DNA as
a supplementary tumour marker in the differential diagnosis of
primary liver cancer.
Of particular interest, LOH in the serum DNA could be detected
in ﬁve of seven HCC patients with serum AFP less than
20 ng ml
71, the normal range for the healthy adults. Previous
study found that approximately one third of small HCC (less than
3 cm) may secrete little or no AFP into the circulation (Ebara et al,
1986). Our data imply that the limitation of low speciﬁcity of AFP
in diagnosing small HCC might be compensated by microsatellite
analysis on cell-free DNA in cancer patients. It will be especially
valuable in patients with poor liver function or ascites, in which
further diagnostic investigation is prohibited. A prospective study
is required to validate the importance of this molecular technique
in the multimodality therapy for HCC.
We showed that the detection of HCC (71.4% sensitivity and
100% speciﬁcity) is feasible by screening the serum samples with
a proﬁle of 19 microsatellite markers. However, a recent study
reported that around 50% of the cirrhotic nodules are monoclonal
and already have chromosomal aberrations (Yeh et al, 2001).
Whether the aberrations are also present in the serum DNA is
currently unknown. Wang et al (2000) reported 87% of sensitivity
in detection of p15/p16 methylation in the circulating DNA of
HCC patients. Although the results seem to be better than we have
in monitoring the proﬁle of microsatellite markers, both the ability
of differential diagnosis of HCC from CC and their value in
patients having AFP below reference range were not examined.
As a result, the impact of these observations in the development
of HCC and/or cell type-speciﬁc genetic markers needs to be clar-
iﬁed in a large cohort of liver disease patients.
In conclusion, we have determined a proﬁle of molecular
markers appropriate for differential diagnosis of primary liver
cancer in the serum. The discovery may permit a high-throughput
screening of hepatocellular carcinoma at an early, and potentially
resectable, stage of disease.
ACKNOWLEDGEMENTS
This study was supported by research grant NSC 89-2314-B-006-
027 from the National Science Council, and research grant
NCKUH 89-051 from the National Cheng Kung University Hospi-
tal, Taiwan, Republic of China.
REFERENCES
Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey
C, Anker P (1996) Microsatellite alterations in plasma DNA of small cell
lung cancer patients. Nat Med 2: 1033–1035
Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub
E, Stroun M, Anker P (1999) Detecting tumor-related alterations in plasma
or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 5:
2297–2303
Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D,
Beaune P, Zucman J, Laurent-Puig P (2000) Detection of plasma tumor
DNA in head and neck squamous cell carcinoma by microsatellite typing
and p53 mutation analysis. Cancer Res 60: 707–711
Ding SF, Delhanty JD, Bowles L, Dooley JS, Wood CB, Habib N (1993) A.
Loss of constitutional heterozygosity on chromosomes 5 and 17 in cholan-
giocarcinoma. Br J Cancer 67: 1007–1010
Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, Morita
M, Saisho H, Tsuchiya Y, Okuda K (1986) Natural history of minute hepa-
tocellular carcinoma smaller than three centimeters complicating cirrhosis.
A study in 22 patients. Gastroenterology 90: 289–298
Eisenberger CF, Schoenberg M, Enger C, Hortopan S, Shah S, Chow NH,
Marshall FF, Sidransky D (1999) Diagnosis of renal cancer by molecular
urinalysis. J Natl Cancer Inst 91: 2028–2032
El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma
in the United States. N Engl J Med 340: 745–750
Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, Fuku-
sato T, Uekusa T, Takagaki T, Kadowaki N, Shirai T (2000) Genetic
classiﬁcation of combined hepatocellular-cholangiocarcinoma. Hum
Pathol 31: 1011–1017
Goessl C, Heicappell R, Munker R, Anker P, Stroun M, Krause H, Muller M,
Miller K (1998) Microsatellite analysis of plasma DNA from patients with
clear cell renal carcinoma. Cancer Res 58: 4728–4732
Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J
(1998) Molecular detection of genetic alterations in the serum of colorectal
cancer patients. Cancer Res 58: 1405–1407
Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A (1997) Comprehensive
allelotyping of human hepatocellular carcinoma. Oncogene 14: 2927–2933
Nunes DN, Kowalski LP, Simpson AJ (2001) Circulating tumor-derived DNA
may permit the early diagnosis of head and neck squamous cell carcino-
mas. Int J Cancer 92: 214–219
Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, Katsura N,
Nishitai R, Takeyama O, Fukumoto M, Yamaoka Y (2000) Comprehensive
allelotype study of hepatocellular carcinoma: potential differences in path-
ways to hepatocellular carcinoma between hepatitis B virus-positive and –
negative tumors. Hepatology 31: 1073–1079
Okuda K, Kubo Y, Okazaki N, Arishima T, Hashimoto M (1977) Clinical
aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a
study of 57 autopsy-proven cases. Cancer 39: 232–246
Piao Z, Park C, Park JH, Kim H (1998) Allelotype analysis of hepatocellular
carcinoma. Int J Cancer 75: 29–33
Sasaki A, Kawano K, Aramaki M, Ohno T, Tahara K, Takeuchi Y, Yoshida T,
Kitano S (2001) Clinicopathologic study of mixed hepatocellular and
cholangiocellular carcinoma: modes of spreading and choice of surgical
treatment by reference to macroscopic type. J Surg Oncol 76: 37–46
Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F,
Provencio M, San Martin S, Espana P, Bonilla F (1999) Presence of tumor
DNA in plasma of breast cancer patients: clinicopathological correlations.
Cancer Res 59: 3251–3256
Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U (1999)
Detection of microsatellite alterations in plasma DNA of non-small cell
lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 5:
2689–2692
Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA,
Tavecchio L (2001) Analysis of circulating tumor DNA in plasma at diag-
nosis and during follow-up of lung cancer patients. Cancer Res 61: 4675–
4678
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Molecular diagnosis of liver cancer in the serum
Y-C Chang et al
1452
British Journal of Cancer (2002) 87(12), 1449–1453 ã 2002 Cancer Research UKTsuji M, Kashihara T, Terada N, Mori H (1999) An immunohistochemical
study of hepatic atypical adenomatous hyperplasia, hepatocellular carcino-
ma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic
antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and
19. Pathol Int 49: 310–317
Wang HN, Lo YM, Yeo W, Lau WY, Johnson PJ (2000) Frequent p15 promo-
ter methylation in tumor and peripheral blood from hepatocellular
carcinoma patients. Clin Cancer Res 6: 3516–3521
Yeh SH, Chen PJ, Lai MY, Chen DS (1996) Allelic loss on chromosomes 4q
and 16q in hepatocellular carcinoma: association with elevated alpha-feto-
protein production. Gastroenterology 110: 184–192
Yeh SH, Chen PJ, Shau WY, Chen YW, Lee PH, Chen JT, Chen DS (2001)
Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocel-
lular carcinoma. Gastroenterology 121: 699–709
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Molecular diagnosis of liver cancer in the serum
Y-C Chang et al
1453
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1449–1453